RRC ID 12446
Author Ono HA, Davydova JG, Adachi Y, Takayama K, Barker SD, Reynolds PN, Krasnykh VN, Kunisaki C, Shimada H, Curiel DT, Yamamoto M.
Title Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer.
Journal J Gastroenterol
Abstract BACKGROUND:Gastric cancer is the fourth most common malignancy worldwide. Adenoviral vectors (Ads) have been applied for gene therapy of various cancers because of their high transduction efficiency. However, the infectivity of gastrointestinal cancer cells is poor due to the limited expression of the Coxsackie-adenovirus receptor (CAR). In addition, few tumor-specific promoters (TSPs) have been characterized for this type of cancer. To overcome these problems, we proposed TSP-driven conditionally replicating adenoviruses (CRAds) with fiber modification for virotherapy of gastric cancer.
METHODS:We assessed the expression profile of eight TSPs in gastric cancer cell lines and evaluated promising candidates in the context of CRAd cytocidal effect. Next, infectivity enhancement by fiber modifications was analyzed in the gastric cancer cell lines. Finally, we combined the TSP-driven CRAds of choice with the fiber modifications to augment the killing effect.
RESULTS:Out of the eight TSPs, the midkine (MK) and cyclooxygenase-2 (Cox-2M and Cox-2L) promoters showed high transcriptional activity in gastric cancer cells. When these promoters were used in a CRAd context, Cox-2 CRAds elicited the strongest cytocidal effect. The greatest infectivity enhancement was observed with adenoviral vectors displaying 5/3 chimeric fibers. Likewise, Cox-2 CRAds with 5/3 chimeric fibers showed the strongest cytocidal effect in gastric cancer cell lines. Therefore, Cox-2 CRAds with 5/3 chimeric fiber modification showed good selectivity and infectivity in gastric cancer cells to yield enhanced oncolysis.
CONCLUSIONS:Cox-2 CRAds with 5/3 chimeric fiber modification are promising for virotherapy of gastric cancer.
Volume 40(1)
Pages 31-42
Published 2005-1-1
DOI 10.1007/s00535-004-1490-y
PMID 15692787
MeSH Adenoviridae / drug effects Adenoviridae / physiology Cell Line, Tumor Coxsackie and Adenovirus Receptor-Like Membrane Protein Cyclooxygenase 2 / drug effects Cyclooxygenase 2 / genetics Cytokines / drug effects Cytokines / genetics Enhancer Elements, Genetic / drug effects Enhancer Elements, Genetic / genetics* Gastrin-Releasing Peptide / therapeutic use Gastrointestinal Agents / therapeutic use Gene Expression Regulation, Viral / drug effects Gene Expression Regulation, Viral / genetics Genetic Vectors / drug effects Genetic Vectors / genetics* Genetic Vectors / therapeutic use* Humans Integrins / biosynthesis Integrins / drug effects Integrins / genetics Midkine Oncolytic Virotherapy Promoter Regions, Genetic / drug effects Promoter Regions, Genetic / genetics Proteinase Inhibitory Proteins, Secretory Proteins / therapeutic use Receptors, Virus / biosynthesis Receptors, Virus / drug effects Receptors, Virus / genetics Serine Proteinase Inhibitors / therapeutic use Stomach Neoplasms / genetics* Stomach Neoplasms / therapy* Stomach Neoplasms / virology Transcription, Genetic / drug effects Transcription, Genetic / genetics Vascular Endothelial Growth Factor A / therapeutic use Virus Replication / drug effects Virus Replication / genetics
IF 6.132
Times Cited 32
Human and Animal Cells